找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Exon Skipping and Inclusion Therapies; Methods and Protocol Toshifumi Yokota,Rika Maruyama Book 2018 Springer Science+Business Media, LLC,

[復(fù)制鏈接]
樓主: 短暫
41#
發(fā)表于 2025-3-28 16:53:50 | 只看該作者
42#
發(fā)表于 2025-3-28 22:13:48 | 只看該作者
43#
發(fā)表于 2025-3-29 02:21:02 | 只看該作者
Restoration of Dystrophin Protein Expression by Exon Skipping Utilizing CRISPR-Cas9 in Myoblasts Derfor myofiber integrity. Exon skipping therapy is an emerging strategy for restoring the open reading frame of the . gene to produce functional protein in DMD patients by skipping single or multiple exons. Although antisense oligonucleotides are able to target pre-mRNA for exon skipping, their half-l
44#
發(fā)表于 2025-3-29 04:29:43 | 只看該作者
45#
發(fā)表于 2025-3-29 09:22:42 | 只看該作者
In Vivo Evaluation of Dystrophin Exon Skipping in , Miceinvolves the following two aspects: (1) efficiency and accuracy of exon skipping and levels of dystrophin expression determined by RT-PCR, immunochemistry, and western blotting; (2) therapeutic effects on muscle pathology and functions assessed by histology and functional assays including grip stren
46#
發(fā)表于 2025-3-29 15:08:21 | 只看該作者
Exon 51 Skipping Quantification by Digital Droplet PCR in del52hDMD/, Mice protein. Antisense oligonucleotide (AON)-mediated exon skipping has been developed as a method to restore the reading frame, which allows the synthesis of internally truncated, but partially functional dystrophin proteins, as found in the less severe Becker muscular dystrophy (BMD). This approach i
47#
發(fā)表于 2025-3-29 17:54:41 | 只看該作者
48#
發(fā)表于 2025-3-29 20:20:55 | 只看該作者
https://doi.org/10.1007/978-3-031-14406-6ations, and its evolution into the approach we are now familiar with. We give a more extensive history of exon skipping in particular, as it is the splice modulation approach given the most focus in this book.
49#
發(fā)表于 2025-3-30 00:55:59 | 只看該作者
Giordano Zambelli,Luciano Morganting authorization by the US Food and Drug Administration (FDA), on the condition that additional postapproval trials show clinical benefit. Permanent exon skipping achieved at the DNA level using clustered regularly interspaced short palindromic repeats (CRISPR) technology holds promise in current pr
50#
發(fā)表于 2025-3-30 07:47:40 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-13 05:56
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
苗栗县| 成都市| 蓝田县| 边坝县| 碌曲县| 日土县| 阿图什市| 孝义市| 德格县| 手机| 囊谦县| 甘洛县| 开鲁县| 伊通| 玉林市| 莱州市| 青阳县| 阳泉市| 绥阳县| 藁城市| 普兰县| 山东| 渑池县| 莫力| 阿拉善右旗| 房产| 新密市| 临夏县| 定边县| 湾仔区| 衡水市| 建阳市| 县级市| 抚顺市| 海晏县| 宜章县| 宜宾县| 勐海县| 襄樊市| 东源县| 兴山县|